MaxCyte has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.13, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MaxCyte will likely underperform. MaxCyte right now secures a risk of 4.53%. Please verify MaxCyte semi variance, as well as the relationship between the daily balance of power and price action indicator , to decide if MaxCyte will be following its current price movements.
Risk-Adjusted Performance
Soft
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in MaxCyte are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, MaxCyte may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
If you would invest 158.00 in MaxCyte on September 30, 2025 and sell it today you would earn a total of 3.00 from holding MaxCyte or generate 1.9% return on investment over 90 days. MaxCyte is currently generating 0.1309% in daily expected returns and assumes 4.5258% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than MaxCyte, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days MaxCyte is expected to generate 6.35 times more return on investment than the market. However, the company is 6.35 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.
MaxCyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MaxCyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MaxCyte, and traders can use it to determine the average amount a MaxCyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0289
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
MXCT
Huge Risk
Negative Returns
Based on monthly moving average MaxCyte is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MaxCyte by adding it to a well-diversified portfolio.
MaxCyte Fundamentals Growth
MaxCyte Stock prices reflect investors' perceptions of the future prospects and financial health of MaxCyte, and MaxCyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MaxCyte Stock performance.
Assessing MaxCyte's fundamental ratios provides investors with valuable insights into MaxCyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MaxCyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about MaxCyte performance evaluation
Checking the ongoing alerts about MaxCyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MaxCyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
MaxCyte had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 38.63 M. Net Loss for the year was (41.05 M) with profit before overhead, payroll, taxes, and interest of 27.53 M.
MaxCyte currently holds about 240.89 M in cash with (27.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating MaxCyte's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate MaxCyte's stock performance include:
Analyzing MaxCyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MaxCyte's stock is overvalued or undervalued compared to its peers.
Examining MaxCyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating MaxCyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MaxCyte's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of MaxCyte's stock. These opinions can provide insight into MaxCyte's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating MaxCyte's stock performance is not an exact science, and many factors can impact MaxCyte's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.